The stock of Ligand Pharmaceuticals, Inc. (NASDAQ: LGND) has increased by 9.75 when compared to last closing price of 73.22.Despite this, the company has seen a gain of 12.52% in its stock price over the last five trading days. Zacks Investment Research reported 2024-05-08 that Ligand Pharmaceuticals (LGND) reports mixed first-quarter results. Management reiterates the 2024 financial outlook.
Is It Worth Investing in Ligand Pharmaceuticals, Inc. (NASDAQ: LGND) Right Now?
The price-to-earnings ratio for Ligand Pharmaceuticals, Inc. (NASDAQ: LGND) is above average at 15.11x, Company’s 36-month beta value is 1.00.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for LGND is 16.84M, and currently, short sellers hold a 4.91% ratio of that floaft. The average trading volume of LGND on May 09, 2024 was 180.01K shares.
LGND’s Market Performance
The stock of Ligand Pharmaceuticals, Inc. (LGND) has seen a 12.52% increase in the past week, with a -1.40% drop in the past month, and a 7.85% gain in the past quarter. The volatility ratio for the week is 4.53%, and the volatility levels for the past 30 days are at 3.58% for LGND. The simple moving average for the last 20 days is 8.48% for LGND’s stock, with a simple moving average of 19.82% for the last 200 days.
Analysts’ Opinion of LGND
Many brokerage firms have already submitted their reports for LGND stocks, with Stephens repeating the rating for LGND by listing it as a “Overweight.” The predicted price for LGND in the upcoming period, according to Stephens is $200 based on the research report published on April 14, 2021 of the previous year 2021.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see LGND reach a price target of $310, previously predicting the price at $229. The rating they have provided for LGND stocks is “Buy” according to the report published on February 04th, 2021.
Barclays gave a rating of “Overweight” to LGND, setting the target price at $156 in the report published on October 06th of the previous year.
LGND Trading at 7.87% from the 50-Day Moving Average
After a stumble in the market that brought LGND to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -15.03% of loss for the given period.
Volatility was left at 3.58%, however, over the last 30 days, the volatility rate increased by 4.53%, as shares sank -0.52% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -9.91% lower at present.
During the last 5 trading sessions, LGND rose by +12.52%, which changed the moving average for the period of 200-days by +20.73% in comparison to the 20-day moving average, which settled at $74.06. In addition, Ligand Pharmaceuticals, Inc. saw 12.52% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LGND starting from Sabba Stephen L, who sale 1,893 shares at the price of $74.30 back on Mar 05 ’24. After this action, Sabba Stephen L now owns 28,926 shares of Ligand Pharmaceuticals, Inc., valued at $140,650 using the latest closing price.
Espinoza Octavio, the Chief Financial Officer of Ligand Pharmaceuticals, Inc., sale 140 shares at $88.46 during a trade that took place back on Feb 28 ’24, which means that Espinoza Octavio is holding 29,755 shares at $12,384 based on the most recent closing price.
Stock Fundamentals for LGND
Current profitability levels for the company are sitting at:
- -0.02 for the present operating margin
- 0.94 for the gross margin
The net margin for Ligand Pharmaceuticals, Inc. stands at 0.79. The total capital return value is set at 0.02. Equity return is now at value 13.26, with 11.17 for asset returns.
Currently, EBITDA for the company is 51.22 million with net debt to EBITDA at -0.0. When we switch over and look at the enterprise to sales, we see a ratio of 12.2. The liquidity ratio also appears to be rather interesting for investors as it stands at 20.70.
Conclusion
In a nutshell, Ligand Pharmaceuticals, Inc. (LGND) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
